Core Viewpoint - MicroPort Scientific Corporation (微创机器人-B) reported a significant increase in revenue and a reduction in losses for the fiscal year 2025, driven by the successful commercialization of its core product, the TiMeye® surgical robot [1] Financial Performance - The company achieved a revenue of 5.51 billion RMB, representing a year-on-year growth of 114.2% [1] - The loss attributable to equity shareholders narrowed to 250 million RMB, a decrease of 61.1% compared to the previous year [1] Product and Market Expansion - The revenue growth was primarily attributed to breakthroughs in the commercialization of the TiMeye® surgical robot, with rapid sales growth noted [1] - The company experienced significant success in expanding its overseas market, signing over 100 new orders in international markets throughout the year [1] - Sales revenue from overseas markets increased to more than five times that of the previous year, showcasing growth that far exceeds the industry average [1]

Core Viewpoint - MicroPort Scientific Corporation (02252) has shown significant growth in its 2025 fiscal year, with a revenue increase of 114.2% year-on-year, primarily driven by the commercialization of its core product, the TiMAY® laparoscopic surgical robot [5]. Financial Performance - The company's revenue reached 5.51 billion RMB, reflecting a substantial increase compared to the previous year [5]. - The loss attributable to equity shareholders was 250 million RMB, which represents a 61.1% reduction year-on-year [5]. Product and Market Expansion - The revenue growth is largely attributed to breakthroughs in the commercialization of the TiMAY® laparoscopic surgical robot, with rapid sales growth noted [5]. - The company has made significant strides in expanding its overseas market, signing over 100 new orders in international markets throughout the year [5]. - Sales revenue from overseas markets increased to more than five times that of the previous year, indicating a growth rate that far exceeds the industry average, showcasing strong global expansion momentum [5].

Core Viewpoint - Micron Robotics-B (02252.HK) reported significant revenue growth and reduced net loss for the fiscal year ending December 31, 2025, indicating strong operational improvements and market expansion [1] Financial Performance - The company recorded revenue of RMB 551 million, representing a year-on-year increase of 114.2% [1] - The net loss for the year was RMB 254 million, a reduction of 60.7% compared to the previous year [1] - Basic loss per share was RMB 0.24 [1] Operational Highlights - The substantial revenue increase was primarily driven by breakthroughs in the commercialization of the core product, the Tumai® laparoscopic surgical robot [1] - Sales growth was particularly strong in overseas markets, with over 100 new orders signed in these regions [1] - Overseas market sales revenue was more than five times that of the previous year, significantly outpacing industry averages and demonstrating robust global expansion momentum [1]

Core Viewpoint - MicroPort Scientific Corporation (微创机器人-B) is experiencing a significant stock price increase ahead of its earnings announcement, with a rise of 3.64% to HKD 25.06, and a trading volume of HKD 206 million [1] Financial Performance - The company plans to hold a board meeting on March 26 to consider and approve its full-year results for the fiscal year ending December 31, 2025 [1] - Revenue is expected to grow approximately 110% to 120% year-on-year for the fiscal year ending December 31, 2025 [1] - Adjusted net loss is projected to be no more than HKD 240 million, representing a reduction of over 50% compared to the previous year [1] Product and Market Development - The substantial revenue increase is primarily attributed to the breakthrough commercialization of the TiMAY® laparoscopic surgical robot [1] - Sales growth has been particularly strong in overseas markets, with over 100 new orders signed in these regions throughout the year [1] - Overseas market sales revenue is expected to exceed five times that of the previous year [1]

Investment Rating - The industry maintains a "Neutral" rating, with specific company ratings of "Buy" for Heng Rui Pharmaceutical (600276) and "Increase" for WuXi Biologics (603259) [46] Core Insights - The recent national drug procurement has been stable, with active participation from companies and continued benefits for patients [8][9] - The issuance of the "National Basic Drug Directory Management Measures" aims to enhance the management of essential medicines [10][11] - Heng Rui Pharmaceutical reported positive top-line results for its GLP-1/GIP dual receptor agonist, indicating significant weight loss in clinical trials [12] - The approval of Mu Feng Da® for the treatment of adult type 2 diabetes marks a significant development in the market [12] Industry News - The national drug procurement involved 316 commonly used drugs across 26 therapeutic areas, with a high participation rate from over 5,100 medical institutions and 1,091 companies [8][9] - The procurement process has been standardized, allowing companies to bid online once for nationwide sales, significantly reducing costs [9] - The management measures for the national basic drug directory have been revised to include legal policy bases and optimize the directory structure [10][11] Company Announcements - Innovent Biologics has entered a global strategic partnership with Eli Lilly to advance new drug development in oncology and immunology [26] - Kelun Pharmaceutical's TROP2 ADC has received approval for a fourth indication from the NMPA [27] - Heng Rui Pharmaceutical's drug has been included in the list of breakthrough therapy products, and its application for marketing approval has been accepted for priority review [28] - WuXi Biologics has forecasted a positive earnings outlook, expecting a revenue increase of approximately 16.7% [30] Market Review - The Shanghai Composite Index rose by 1.43%, while the Shenzhen Component Index increased by 2.37%, with the SW Pharmaceutical and Biotech Index up by 0.23% [36] - The industry’s price-to-earnings ratio (TTM) stands at 51.17, with a valuation premium of 259% compared to the CSI 300 [40] Weekly Strategy - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, while also monitoring performance recovery indicators [46]

Core Viewpoint - MicroPort Robotics-B (02252) has achieved a significant milestone with over 200 global commercial orders for its TiMeye® laparoscopic surgical robot, indicating widespread recognition of its clinical value and safety [1] Group 1: Company Performance - As of the announcement date, the company has completed nearly 130 installations of the TiMeye system, demonstrating its growing market presence [1] - The stock opened over 3% higher and is currently trading at 26.8 HKD with a transaction volume of 2.987 million HKD [1] Group 2: Product Development - The TiMeye system is the first remote surgical robot approved for commercial use, with approvals in nearly 10 countries including China, India, and Brazil, covering regions with nearly half of the global population [1] - The system has successfully completed nearly 800 remote surgeries across over 20 countries, maintaining a 100% success rate [1] Group 3: Market Recognition - The increase in commercial orders and installations reflects the system's systematic certification of safety, stability, and reliability, as recognized by surgeons from various countries and medical backgrounds [1]

Major Events - Fuhong Hanlin (02696) received NMPA approval for the Phase I clinical trial application of HLX15-SC for the treatment of multiple myeloma [1] - Kangzheng Pharmaceutical (00867) signed an exclusive distribution agreement for the original drug Lidoderm® lidocaine gel patch [1] - MicroPort Robotics-B (02252) surpassed 200 global commercial orders for the Tumai® laparoscopic surgical robot [1] - BGO Group (08220) plans to acquire a proposal from Stephen Chow at a discount of approximately 91.79% [1] - Kogee Pharmaceuticals-B (02171) signed a strategic cooperation agreement with Shanghai Jinguang Enterprise Development to build a commercial production base for CAR-T cell therapy products in Jinshan [1] Operating Performance - China Resources Land (01109) reported total contract sales of approximately 11.65 billion yuan in January, a year-on-year increase of 0.4% [1] - Hua Hong Semiconductor (01347) announced a profit attributable to the parent company of 54.881 million USD for 2025, a year-on-year decrease of 5.6% [1] - China Coal Energy (01898) reported coal sales of 20.05 million tons in January, a year-on-year decrease of 7.3% [1] - China Metallurgical Group (01618) signed new contracts worth 73.65 billion yuan in January [1] - China Communications Construction (01800) reported new contracts worth 1.883672 trillion yuan for 2025, a year-on-year increase of 0.13% [1]

Group 1: Film Industry Initiatives - The National Film Administration and the Ministry of Commerce have organized a "Film+" consumption pilot program in 16 selected cities to enhance film-related consumption and economic development [1] - The pilot cities will focus on increasing film viewing consumption, innovating cinema experiences, expanding film derivative consumption, and creating a "Film+" consumption brand [1] - The initiative aims to extend the film industry chain and promote a healthy film consumption culture, thereby meeting the growing demand for quality life among the public [1] Group 2: Market Trends and Stock Performance - U.S. stock indices experienced significant declines, with the Dow Jones down 1.34%, S&P 500 down 1.57%, and Nasdaq down 2.03%, indicating a bearish trend in the market [2] - Major technology stocks fell sharply, with Apple down 5% and Amazon, Meta, and Tesla down over 2%, reflecting broader market concerns [2] - The Hang Seng Index ADR also dropped by 1.62%, suggesting a negative sentiment in the Hong Kong market [2] Group 3: Corporate Earnings and Forecasts - Huahong Semiconductor reported a 22.4% year-on-year increase in sales revenue, reaching approximately $660 million, but net profit decreased by 32.2% [9] - China Tongfu issued a profit warning, expecting a revenue decline of 5% to 8% and a net profit drop of 25% to 30% compared to the previous year, primarily due to decreased earnings in its nuclear medical equipment division [10] - Skyworth Group anticipates a 30% decrease in profit for the fiscal year ending December 31, 2025, attributed to the ongoing downturn in the Chinese real estate market [11] Group 4: Corporate Transactions and Developments - Chang'an Minsheng Logistics announced the sale of 16.03% of its shares by its major shareholder, Meiji Logistics, to Luhang Zhongbang, marking a significant change in ownership [7] - Micron Robotics-B reported over 200 global commercial orders for its TUMAI® laparoscopic surgical robot, indicating strong market acceptance and clinical value [8] - Bigao Group is seeking to restructure its convertible bond terms with Stephen Chow, proposing a significant discount on the share price, which may trigger a mandatory general offer [12]

Core Insights - The core product, the TUMAI® laparoscopic surgical robot, has surpassed 200 global commercial orders, covering nearly 50 countries and regions, with approximately 130 installations completed [1] - The significant increase in commercial orders and installations indicates the sustained and widespread recognition of TUMAI's clinical value globally, serving as a systematic certification of its safety, stability, and reliability [1] - Surgeons from various countries and medical systems are integrating TUMAI into their daily surgical practices and long-term academic development [1] Market Performance - Among the nearly 50 countries and regions covered, 12 have more than 5 orders, with strong growth in emerging markets such as India, Brazil, and Argentina; India has accumulated 14 orders, while Brazil has over 10 [1] - Developed markets continue to show breakthroughs, with Spain and Australia emerging as rapid growth points [1] - TUMAI's commercialization has established a new pattern of multi-regional collaborative resonance globally, spanning both emerging markets in developing countries and mature healthcare systems in developed nations [1] Clinical Application - TUMAI has made significant progress in the depth of single-center clinical applications, with several medical institutions having completed over 100 surgeries using TUMAI [1] - The application of TUMAI spans multiple specialties, including urology, general surgery, thoracic surgery, gynecology, pediatric surgery, and head and neck surgery [1] Remote Surgery Development - TUMAI is the first remote surgical robot system approved for commercial application, having received market approval in nearly 10 countries, including China, India, and Brazil [2] - The application of TUMAI covers regions where nearly half of the global population resides and has entered a phase of normalized and scaled clinical application [2] - As of now, TUMAI has completed nearly 800 remote surgeries across over 20 countries, maintaining a 100% success rate [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 本公司董事會（「董事會」）欣然宣佈，截至本公告日，本集團核心產品圖邁®腔 鏡手術機器人（「圖邁」）全球商業化訂單突破200台，覆蓋近50個國家和地區， 已完成商業化裝機近130台。圖邁商業化訂單和裝機規模的再次里程碑式躍升， 標誌著其臨床價值在全球範圍內獲得持續、廣泛的認可，是對圖邁安全性、穩 定性、可靠性的系統性認證。來自不同國家、不同醫療體系、不同專科背景的 外科醫生，正在以真實而審慎的臨床決策，將圖邁納入日常手術實踐與長期學 科建設之中。 在已覆蓋的近50個國家和地區中，訂單數超5台的達12個，新興市場代表印度、 巴西、阿根廷增長強勁，其中印度累計訂單已達14台，巴西超過10台；發達國 家市場持續突破，西班牙、澳大利亞等國家成為快速增長點。圖邁商業化已在 全球範圍內形成多區域協同共振的新格局，貫穿發展中國家新興市場以及發 達國家成熟醫療體系。 （於中華人民共和國註冊成立的股份有限公司） – 1 – ...